QALY Control: House Bill Would Ban Cost-Effectiveness Tool In US Programs
No one seems eager to defend the QALY tool as a House Republican bill seeks to prohibit any federal agency from using Quality Adjusted Life Years as a formula to determine pricing.
You may also be interested in...
Prohibition by Health and Human Services Department Office of Civil Rights would apply to use of such metrics in determining formulary access but not to use in ‘academic’ research.
Day after taking chair of committee with FDA oversight, Rodgers criticizes White House’s declaration extending COVID-19 public health emergency. House Appropriation chair Granger prioritizes cutting spending, boosting military.
Biopharma likely approves of the Administration’s concern that QALYs, a commonly used metric in cost effectiveness evaluations, may not be appropriate for drug pricing reform policies because it could disadvantage people with disabilities.